109 related articles for article (PubMed ID: 34007088)
1. Design and synthesis of pyrazolone-based compounds as potent blockers of SARS-CoV-2 viral entry into the host cells.
Obakachi VA; Kushwaha ND; Kushwaha B; Mahlalela MC; Shinde SR; Kehinde I; Karpoormath R
J Mol Struct; 2021 Oct; 1241():130665. PubMed ID: 34007088
[TBL] [Abstract][Full Text] [Related]
2. Inhibitory mechanism of Ambroxol and Bromhexine Hydrochlorides as potent blockers of molecular interaction between SARS-CoV-2 spike protein and human angiotensin-converting Enzyme-2.
Kehinde IA; Egbejimi A; Kaur M; Onyenaka C; Adebusuyi T; Olaleye OA
J Mol Graph Model; 2022 Jul; 114():108201. PubMed ID: 35487151
[TBL] [Abstract][Full Text] [Related]
3. Screening of inhibitors against SARS-CoV-2 spike protein and their capability to block the viral entry mechanism: A viroinformatics study.
Farouk AE; Baig MH; Khan MI; Park T; Alotaibi SS; Dong JJ
Saudi J Biol Sci; 2021 Jun; 28(6):3262-3269. PubMed ID: 33654454
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of molecular interaction, physicochemical parameters and conserved pattern of SARS-CoV-2 Spike RBD and hACE2: in silico and molecular dynamics approach.
Chakraborty C; Sharma AR; Mallick B; Bhattacharya M; Sharma G; Lee SS
Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1708-1723. PubMed ID: 33629340
[TBL] [Abstract][Full Text] [Related]
5. Properties of Coronavirus and SARS-CoV-2.
Malik YA
Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
[TBL] [Abstract][Full Text] [Related]
6. Computational drug repurposing strategy predicted peptide-based drugs that can potentially inhibit the interaction of SARS-CoV-2 spike protein with its target (humanACE2).
Egieyeh S; Egieyeh E; Malan S; Christofells A; Fielding B
PLoS One; 2021; 16(1):e0245258. PubMed ID: 33417604
[TBL] [Abstract][Full Text] [Related]
7. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
8. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein.
Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG
J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194
[TBL] [Abstract][Full Text] [Related]
9. Design of Potent Membrane Fusion Inhibitors against SARS-CoV-2, an Emerging Coronavirus with High Fusogenic Activity.
Zhu Y; Yu D; Yan H; Chong H; He Y
J Virol; 2020 Jul; 94(14):. PubMed ID: 32376627
[TBL] [Abstract][Full Text] [Related]
10. Coevolution, Dynamics and Allostery Conspire in Shaping Cooperative Binding and Signal Transmission of the SARS-CoV-2 Spike Protein with Human Angiotensin-Converting Enzyme 2.
Verkhivker G
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33158276
[TBL] [Abstract][Full Text] [Related]
11. Human Surfactant Protein D Binds Spike Protein and Acts as an Entry Inhibitor of SARS-CoV-2 Pseudotyped Viral Particles.
Hsieh MH; Beirag N; Murugaiah V; Chou YC; Kuo WS; Kao HF; Madan T; Kishore U; Wang JY
Front Immunol; 2021; 12():641360. PubMed ID: 34054808
[TBL] [Abstract][Full Text] [Related]
12. ACE-2-Derived Biomimetic Peptides for the Inhibition of Spike Protein of SARS-CoV-2.
Panda SK; Sen Gupta PS; Biswal S; Ray AK; Rana MK
J Proteome Res; 2021 Feb; 20(2):1296-1303. PubMed ID: 33472369
[TBL] [Abstract][Full Text] [Related]
13. COVID-19 pandemic: Insights into structure, function, and hACE2 receptor recognition by SARS-CoV-2.
Mittal A; Manjunath K; Ranjan RK; Kaushik S; Kumar S; Verma V
PLoS Pathog; 2020 Aug; 16(8):e1008762. PubMed ID: 32822426
[TBL] [Abstract][Full Text] [Related]
14. Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.
Barh D; Tiwari S; Silva Andrade B; Giovanetti M; Almeida Costa E; Kumavath R; Ghosh P; Góes-Neto A; Carlos Junior Alcantara L; Azevedo V
F1000Res; 2020; 9():576. PubMed ID: 32802318
[No Abstract] [Full Text] [Related]
15. 1,2,3,4,6-Pentagalloyl Glucose, a RBD-ACE2 Binding Inhibitor to Prevent SARS-CoV-2 Infection.
Chen RH; Yang LJ; Hamdoun S; Chung SK; Lam CW; Zhang KX; Guo X; Xia C; Law BYK; Wong VKW
Front Pharmacol; 2021; 12():634176. PubMed ID: 33897423
[TBL] [Abstract][Full Text] [Related]
16. Contact residue contributions to interaction energies between SARS-CoV-1 spike proteins and human ACE2 receptors.
Rodriguez JH; Gupta A
Sci Rep; 2021 Jan; 11(1):1156. PubMed ID: 33441985
[TBL] [Abstract][Full Text] [Related]
17. An Active Site Inhibitor Induces Conformational Penalties for ACE2 Recognition by the Spike Protein of SARS-CoV-2.
Williams-Noonan BJ; Todorova N; Kulkarni K; Aguilar MI; Yarovsky I
J Phys Chem B; 2021 Mar; 125(10):2533-2550. PubMed ID: 33657325
[TBL] [Abstract][Full Text] [Related]
18. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
Kim CH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
[TBL] [Abstract][Full Text] [Related]
20. Broad and Differential Animal Angiotensin-Converting Enzyme 2 Receptor Usage by SARS-CoV-2.
Zhao X; Chen D; Szabla R; Zheng M; Li G; Du P; Zheng S; Li X; Song C; Li R; Guo JT; Junop M; Zeng H; Lin H
J Virol; 2020 Aug; 94(18):. PubMed ID: 32661139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
